Is CCCC or CGEN more undervalued in 2026?

CirclFi compares C4 Therapeutics, Inc. (CCCC) and Compugen Ltd. (CGEN) using 13 institutional-grade valuation models. CCCC has a Quality of Company score of 5.3/10 while CGEN scores 9.0/10.

Which is a better buy — CCCC or CGEN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CCCC and CGEN valuations compare?

CCCC at $4.37 and CGEN at $2.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CCCC vs CGEN Valuation Comparison 2026 — Intrinsic Value Analysis

CCCC

Biological Products, (No Diagnostic Substances)

C4 Therapeutics, Inc.

Quality

5.3

out of 10

Value Trap

SAFE

Price

$4.37

Last close

Models

9/13

Active

CGEN

Biological Products, (No Diagnostic Substances)

Compugen Ltd.

Quality

9.0

out of 10

Value Trap

SAFE

Price

$2.63

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CCCC Fair Value	CCCC Upside	CGEN Fair Value	CGEN Upside
Bayesian DCF	Intrinsic	$0.70	-84.0%	$4.07	+54.7%
Earnings Power Value	Intrinsic	—	—	$3.30	+25.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.26	-91.2%	$2.11	-19.6%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CCCC vs CGEN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CCCC vs CGEN — Which Stock Is More Undervalued?

CGEN scores higher with a 9.0/10 quality rating vs CCCC's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing C4 Therapeutics, Inc. (CCCC) and Compugen Ltd. (CGEN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CCCC currently trades at $4.37 with a QOC of 5.3/10, while CGEN trades at $2.63 with a QOC of 9.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).